Quick Answer
Gossamer Bio, Inc. reported Cash and Equivalents of $37.73 million for fiscal year 2025.
Gossamer Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $37.73M | -18.1% |
| 2024 | $46.07M | +43.5% |
| 2023 | $32.11M | -71.3% |
| 2022 | $111.97M | -38.9% |
| 2021 | $183.40M | -62.3% |
| 2020 | $486.06M | +260.0% |
| 2019 | $135.03M | +28.3% |
| 2018 | $105.22M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.93M | -68.6% | -66.0% |
| June 30, 2025 | $26.31M | -69.7% | -9.3% |
| March 31, 2025 | $29.02M | -25.3% | -37.0% |
| December 31, 2024 | $46.07M | +43.5% | +61.9% |
| September 30, 2024 | $28.46M | -65.5% | -67.2% |
| June 30, 2024 | $86.88M | +134.8% | +123.5% |
| March 31, 2024 | $38.86M | -40.4% | +21.0% |
| December 31, 2023 | $32.11M | -71.3% | -61.1% |
- Gossamer Bio, Inc. showed a decrease of -18.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Gossamer Bio, Inc.’s cash and equivalents has declined by 64.1% (from $105.22 million to $37.73 million).
- The most recent figure is from Gossamer Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: